Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials

This meta-analysis, led by the influential Canadian researcher Serge Gauthier, synthesized data from six randomized, double-blind, placebo-controlled trials that evaluated Cerebrolysin in patients with mild-to-moderate Alzheimer's disease. The studies included a total of 597 patients treated with 30 mL/day of intravenous Cerebrolysin for periods up to 24 weeks.

The analysis demonstrated statistically significant superiority of Cerebrolysin over placebo on three critical outcomes: cognitive function (measured by ADAS-cog+), global clinical change (CIBIC+), and a combined benefit endpoint integrating cognition and clinical impression. Differences were significant both at the early 4-week assessment and at the late 6-month assessment, suggesting both acute and sustained effects.

The safety profile of Cerebrolysin was comparable to placebo across all studies, with low incidence of serious adverse events and excellent tolerability — an important characteristic for a frequently polypharmacy-treated geriatric population. The analysis concluded that the compound shows a favorable benefit-risk ratio.

This work consolidated Cerebrolysin as one of the few therapies with meta-analytic evidence of efficacy in mild-to-moderate Alzheimer's, alongside cholinesterase inhibitors and memantine. The neurotrophic heterogeneity of the porcine hydrolysate (containing fragments similar to BDNF, GDNF, NGF, and CNTF) was proposed as the mechanism behind the observed cognitive and clinical effects.